Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
Ronald F van Vollenhoven,Paul Emery,Clifton O. Bingham,Edward C. Keystone,Roy Fleischmann,Daniel E. Furst,Nicola Tyson,Neil Collinson,P.B. Lehane +8 more
Reads0
Chats0
TLDR
It is demonstrated that rituximab remains generally well tolerated over time and multiple courses, with a safety profile consistent with published data and clinical trial experience.Abstract:
Objectives Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA). Methods Pooled observed case analysis of data from patients with moderate-to-severe, active RA treated with rituximab in a global clinical trial programme. Results As of September 2010, 3194 patients had received up to 17 rituximab courses over 9.5 years (11 962 patient-years). Of these, 627 had >5 years’ follow-up (4418 patient-years). A pooled placebo population (n=818) (placebo+methotrexate (MTX)) was also analysed. Serious adverse event and infection rates generally remained stable over time and multiple courses. The overall serious infection event (SIE) rate was 3.94/ 100 patient-years (3.26/100 patient-years in patients observed for >5 years) and was comparable with placebo+MTX (3.79/100 patient-years). Serious opportunistic infections were rare. Overall, 22.4% (n=717) of rituximab-treated patients developed low immunoglobulin (Ig)M and 3.5% (n=112) low IgG levels for ≥4 months after ≥1 course. SIE rates were similar before and during/after development of low Ig levels; however, in patients with low IgG, rates were higher than in patients who never developed low IgG. Rates of myocardial infarction and stroke were consistent with rates in the general RA population. No increased risk of malignancy over time was observed. Conclusions This analysis demonstrates that rituximab remains generally well tolerated over time and multiple courses, with a safety profile consistent with published data and clinical trial experience. Overall, the findings indicate that there was no evidence of an increased safety risk or increased reporting rates of any types of adverse events with prolonged exposure to rituximab during the 9.5 years of observation.read more
Citations
More filters
Journal ArticleDOI
Rituximab for the treatment of rheumatoid arthritis: an update.
TL;DR: Extended observation of randomized controlled trials in RA does not reveal a significant increase in the incidence of serious infections related to rituximab compared to placebo groups, and the infection rate remains static over time.
Journal ArticleDOI
The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.
TL;DR: The rapidly evolving list of underlying causes ofsecondary antibody deficiency is discussed, specifically focusing on therapies targeting B cells, alongside recent advances in screening, biomarkers of risk for the development of secondary antibody deficiency, diagnosis, monitoring, and management.
Journal ArticleDOI
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Jeffrey R. Curtis,Eun Bong Lee,Irina Kaplan,Kenneth Kwok,Jamie Geier,B. Benda,Koshika Soma,Lisy Wang,R. Riese +8 more
TL;DR: The overall rates and types of malignancies observed in the tofacitinib clinical programme remained stable over time with increasing tofacinib exposure, and standardised incidence ratios were within the expected range of patients with moderate-to-severe RA.
Journal ArticleDOI
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
TL;DR: RCTs are not sensitive enough to assess the risk of reactivation of latent TB infection (LTBI), disease, treatment and background TB rate are associated with different frequencies of active TB.
Journal ArticleDOI
Rituximab for Rheumatoid Arthritis
TL;DR: Rituximab has been a significant addition to the rheumatologists’ armamentarium for the treatment of RA, and patient screening for hypersensitivity to murine proteins, infections, congestive heart failure, pregnancy, and hypogammaglobulinemia is imperative.
References
More filters
Journal ArticleDOI
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Jonathan C. W. Edwards,Leszek Szczepanski,Jacek Szechiński,Anna Filipowicz-Sosnowska,Paul Emery,D. Close,Randall M Stevens,T. Shaw +7 more
TL;DR: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotRexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Journal ArticleDOI
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials
Tim Bongartz,Alex J. Sutton,Michael J. Sweeting,Iain Buchan,Eric L. Matteson,Victor M. Montori +5 more
TL;DR: There is evidence of an increased risk of serious infections and a dose-dependent increasedrisk of malignancies in patients with rheumatoid arthritis treated with anti-TNF antibody therapy.
Journal ArticleDOI
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley Cohen,Paul Emery,Maria Greenwald,Maxime Dougados,Richard Furie,Mark C. Genovese,Edward C. Keystone,J.E. Loveless,Gerd-Rüdiger Burmester,M. Cravets,E. W. Hessey,T. Shaw,Mark C. Totoritis +12 more
TL;DR: At 24 weeks, a single course of rituximab with concomitant MTX therapy provided significant and clinically meaningful improvements in disease activity in patients with active, longstanding RA who had an inadequate response to 1 or more anti-TNF therapies.
Journal ArticleDOI
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Paul Emery,Roy Fleischmann,Anna Filipowicz-Sosnowska,Joy Schechtman,Leszek Szczepanski,Arthur Kavanaugh,Artur Racewicz,Ronald F van Vollenhoven,Nicole F. Li,Sunil Agarwal,E. W. Hessey,T. Shaw +11 more
TL;DR: Both rituximab doses were effective and well tolerated when added to MTX therapy in patients with active rheumatoid arthritis, although intravenous glucocorticoid premedication improved tolerability during the first ritUXimab infusion.
Journal ArticleDOI
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
Eva Baecklund,Anastasia Iliadou,Johan Askling,Anders Ekbom,Anders Ekbom,Carin Backlin,Fredrik Granath,Anca I. Catrina,Richard Rosenquist,Nils Feltelius,Christer Sundström,Lars Klareskog +11 more
TL;DR: Risk of lymphoma is substantially increased in a subset of patients with RA, those with very severe disease, and high inflammatory activity, rather than its treatment, is a major risk determinant.
Related Papers (5)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more